Online inquiry

IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15279MR)

This product GTTS-WQ15279MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Glioma Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15279MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13825MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-10987
GTTS-WQ1725MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ2684MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ5743MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ10186MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LC1004-002
GTTS-WQ13273MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ9386MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ8347MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA hPAM4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW